Content in this topic
Researchers have gotten the green light to deliberately infect people with the coronavirus as part of the world’s first COVID-19 human challenge study.
A universal coronavirus vaccine that protects against multiple coronaviruses could stop the next potential pandemic from ever starting.
The Pfizer vaccine's second dose might not be as necessary as thought — and ultra-cold storage of the COVID-19 vaccine might not be necessary at all.
Can new technology help society eliminate cardiac episodes completely?
Anthony Fauci expects April will be “open season” for COVID-19 vaccines. Here’s why his prediction about COVID-19 vaccine availability appears accurate.
Natural COVID-19 immunity — the kind coronavirus survivors have — is about as robust as the immunity prompted by vaccines.
2020 has put medicine to the forefront like never before. Freethink’s B. David Zarley looked back on the year and chose three medical developments that inspired him.
A new coronavirus mutation is spreading quickly in the U.K. Here’s what we know about the coronavirus strain and what we need to figure out.
British American Tobacco has FDA approval to begin human trials on a tobacco-based COVID-19 vaccine that could potentially be stored at room temperature.
If you have questions about the COVID-19 vaccine approved for use in the U.S., this is your place to find answers.
Influenza’s constant genetic shifting means flu vaccines aim at a moving target. But a universal flu vaccine just passed its phase 1 trials.
Using CRISPR to stop the replication of SIV, a primate virus closely related to HIV, researchers may have taken a step to wiping the virus out in the body.
The FDA has authorized the first over-the-counter COVID-19 test for home use, but buyers still have to send their samples to a lab for processing.
Developers are on the hunt for a warm COVID-19 vaccine, one that could be distributed in places where a reliable cold chain isn’t available.
Congo’s recent success delivering frigid Ebola vaccines to remote areas may provide invaluable experience for a COVID-19 vaccine cold chain.
Several developers have reported incredible coronavirus vaccine progress, so when will we have a COVID-19 vaccine ready for distribution?
Many hospitals in developing countries can’t access the overpriced, high-tech equipment that’s standard in the U.S. Reverse innovation could finally change that.
The University of Oxford's COVID-19 vaccine was up to 90% effective in a phase 3 trial and could be easier to distribute than other coronavirus vaccines.